Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia

Brain Research

Volumn 1019, Issue 1-2, 2004, Pages 210-216

  Matucz, Éva ^a   Móricz, Krisztina ^a   Gigler, Gábor ^a   Simó, Annamária ^a   Barkóczy, József ^a   Lévay, György ^a   Hársing Jr , László G ^a   Szénási, Gábor ^a  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

Cerebral ischemia; Homophthalazine; Ischemia; J: Disorders of the nervous system; Middle cerebral artery occlusion; Neuroprotection

Indexed keywords

7 ACETYL 5 (4 AMINOPHENYL) 7,8 DIHYDRO 8 CYANO 8 METHYL 9H 1,3 DIOXOLO[4,5 H] 2,3 BENZODIAZEPINE; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; EGIS 8332; GYKI 53405; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN TISSUE; CONTROLLED STUDY; ELECTROCOAGULATION; MALE; MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN ISCHEMIA; CEREBRAL INFARCTION; EXCITATORY AMINO ACID ANTAGONISTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA;

EID: 4043102491     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.05.098     Document Type: Article

References (40)

1. Ábrahám G., Sólyom S., Csuzdi E., Berzsenyi P., Ling I., Tarnawa I., Hámori T., Pallagi I., Horváth K., Andrási F., Kapus G., Hársing L.G. Jr., Király I., Patthy M., Horváth G.Y. New non competitive AMPA antagonists. Bioorg. Med. Chem. 8:2000;2127-2143
2. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., Bartkowski H. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 17:1986;1304-1308
3. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 17:1986;472-476
4. Belayev L., Alonso O.F., Busto R., Zhao W., Ginsberg M.D. Middle cerebral artery occlusion in the rat by intraluminal suture: neurological and pathological evaluation of an improved model. Stroke. 27:1996;1616-1623
5. Belayev L., Alonso O.F., Liu Y., Chappell A.S., Zhao W., Ginsberg M.D., Busto R. Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats. Neurotrauma. 18:2001;1031-1038
6. Bleakman D., Ballyk B.A., Schoepp D.D., Palmer A.J., Bath C.P., Sharpe E.F., Wooley M.L., Bufton H.R., Kamboj R.K., Tarnawa I., Lodge D. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology. 35:1996;1689-1702
7. Brint S., Jacewicz M., Kiessling M., Tanabe J., Pulsinelli W. Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J. Cereb. Blood Flow Metab. 8:1988;474-485
8. Burnashev N., Monyer H., Seeburg P.H., Sakmann B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron. 8:1992;189-198
9. Cushing A., Price-Jones M.J., Graves R., Harris A.J., Hughes K.T., Bleakman D., Lodge D. Measurement of calcium flux through ionotropic glutamate receptors using cytostar-T scintillating microplates. J. Neurosci. Methods. 90:1999;33-36
10. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischemic stroke: an integrated view. Trends Neurosci. 22:1999;391-397
11. Fisher M., Garcia J.H. Evolving stroke and the ischemic penumbra. Neurology. 47:1996;884-888
12. Gigler G., Simó A., Lévay G.Y. EGIS-8332, a new non-competitive AMPA antagonist with neuroprotective and anticonvulsive activities, XIXth International Symposium on Cerebral Blood Flow and Metabolism, Copenhagen, Denmark, June 13-17. J. Cereb. Blood Flow Metab. 19(Suppl. 1):1999;S150
13. Gigler G., Simó A., Móricz K., Kapus G., Végh M., Kertész S., Barkóczy J., Szénási G., Lévay G.Y. Pharmacology of a non-competitive AMPA antagonist: EGIS-8332, 3rd Forum of European Neuroscience, Paris, France, July 13-17. FENS Abstr. 1:2002;A224.13
14. Gill R., Sibson N.R., Hatfield R.H., Burdett N.G., Carpenter T.A., Hall L.D., Pickard J.D. A comparison of the early development of ischemic damage following permanent middle cerebral artery occlusion in rats as assessed using magnetic resonance imaging and histology. J. Cereb. Blood Flow Metab. 15:1995;1-11
15. Ginsberg M.D., Busto R. Rodent models of cerebral ischemia. Stroke. 20:1989;1627-1642
16. Gyertyán I., Gigler G., Simó A. The neuroprotective and hypothermic effect of GYKI-52466, a non-competitive α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischemia model. Brain Res. Bull. 50:1999;179-186
17. Hacke W., Donnan G., Fieschi C., Kaste M., von Kummer R., Broderick J.P., Brott T., Frankel M., Grotta J.C., Haley E.C. Jr., Kwiatkowski T., Levine S.R., Lewandowski C., Lu M., Lyden P., Marler J.R., Patel S., Tilley B.C., Albers G., Bluhmki E., Wilhelm M., Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 363:2004;768-774
18. Hock N.H. Brain attack (the stroke continuum). Nurs. Clin. North Am. 34:1999;689-723
19. Kawasaki-Yatsugi S., Ichiki C., Yatsugi S.I., Shimizu-Sasamata M., Yamaguchi T. YM90K, an AMPA receptor antagonist, protects against ischemic damage caused by permanent and transient middle cerebral artery occlusion in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;586-591
20. Kovács A.D., Szabó G. GYKI 53665, a 2,3-benzodiazepine, non-competitively protects cultured neurones against AMPA toxicity. Eur. J. Pharmacol. 331:1997;93-96
21. Kristián T., Gidö G., Kuroda S., Schütz A., Siesjö B.K. Calcium metabolism of focal and penumbral tissues in rats subjected to transient middle cerebral artery occlusion. Exp. Brain Res. 120:1998;503-509
22. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91
23. Margaill I., Parmentier S., Callebert J., Allix M., Boulu R.G., Plotkine M. Short therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive rats. J. Cereb. Blood Flow Metab. 16:1996;107-113
24. Memezawa H., Minamisawa H., Smith M.L., Siesjö B.K. Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat. Exp. Brain Res. 89:1992;67-78
25. Menniti F.S., Buchan A.M., Chenard B.L., Critchett D.J., Ganong A.H., Guanowsky V., Seymour P.A., Welch W.M. CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke. 34:2003;171-176
26. Morris R.G.M., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 319:1986;774-776
27. Oguro K., Oguro N., Kojima T., Grooms S.Y., Calderone A., Zheng X., Bennett M.V., Zukin R.S. Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. J. Neurosci. 19:1999;9218-9227
28. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362
29. Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11:1998;523-569
30. 2+-permeable AMPA receptors in neurological disorders. Trends Neurosci. 20:1997;464-470
31. Shirotani T., Shima K., Iwata M., Kita H., Chigasaki H. Calcium accumulation following middle cerebral artery occlusion in stroke-prone spontaneously hypertensive rats. J. Cereb. Blood Flow Metab. 14:1994;831-836
32. Sólyom S., Tarnawa I. Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr. Pharm. Des. 8:2002;913-939
33. Sonders M.S., Keana J.F., Weber E. Phencyclidine and psychotomimetic sigma opiates: recent insights into their biochemical and physiological sites of action. Trends Neurosci. 11:1988;37-40
34. Szabados T., Gigler G., Gyertyán I., Gacsályi I., Lévay G. Duration of action of GYKI 52466 and its analogues in antiepileptic, antiischaemic and muscle relaxant tests. Neurobiology. 7:1999;87-88
35. Szabados T., Gigler G., Gacsályi I., Gyertyán I., Lévay G. Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405 and GYKI 53655. Brain Res. Bull. 55:2001;387-391
36. Tamura A., Graham D.J., McCulloch J., Teasdale G.M. Focal cerebral ischemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1:1981;53-60
37. Tegos T.J., Kalodiki E., Daskalopoulou S.S., Nicolaides A.N. Stroke: epidemiology, clinical picture, and risk factors. Angiology. 51:2000;793-808
38. Turski L., Huth A., Sheardown M., McDonald F., Neuhaus R., Schneider H.H., Dirnagl U., Wiegand F., Jacobsen P., Ottow E. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc. Natl. Acad. Sci. U. S. A. 95:1998;10960-10965
39. Vizi E.S., Mike A., Tarnawa I. 2,3-Benzodiazepines (GYKI 52466 and analogs): negative allosteric modulators of AMPA receptors. CNS Drug Rev. 2:1996;91-126
40. Yang J., Klaidmann L.K., Chang M.L., Kem S., Sugawara T., Chan P., Adams J.D. Jr. Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model. Pharmacol. Biochem. Behav. 73:2002;901-910